Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ORGANIZATION
ORGANIZATION
- FPMAJ “Not Opposed” to Company Requirements for Receiving Price Maintenance Premium: Kamoya
June 20, 2017
- Reflecting Results of CEA in NHI Prices at Time of Listing Will Be Difficult: FPMAJ Report
June 20, 2017
- FPMAJ Calls for “Cautious” Discussions on Reduction of Price Band for Generic Drugs
June 19, 2017
- FPMAJ Calls for Maintaining Prices for On-Patent Drugs, Lower Price Reduction Rates in Off-Year Revisions
June 19, 2017
- JGA Appreciates Tweaked Honebuto Text on Generics, 80% Goal Achievable on Production Basis
June 13, 2017
- JMA’s Nakagawa Questions Price Difference for LLPs and AGs, Negative about PhRMA Pitch for AWP Alternatives
June 9, 2017
- Membership of Japan Biosimilar Association to Reach 20 Companies in Near Future
June 7, 2017
- Public, Private Donors Put Up US$200-Plus Million for GHIT’s 2nd-Phase Work
June 5, 2017
- Japan Drug Market Could Shrink at CAGR of -2.5% If Price Maintenance Premium Scrapped: EFPIA
June 1, 2017
- JGA Ups Its Lobbying Efforts to Prevent Further Reduction in Price Bands for Generics
June 1, 2017
- Maker FTC Sanctions Member Company for Violating Fair Competition Code
May 30, 2017
- Wholesale Industry FTC to Discuss Prohibiting Free-of-Charge Inventory Transfers between Pharmacies
May 30, 2017
- JPMA Will Be Watching Discussions on Eligibility Criteria for Companies to Receive Price Maintenance Premium
May 29, 2017
- Suzuki to Serve His 3rd Term as JPWA Chief
May 26, 2017
- Japan Microbiome Consortium Inaugurated by Drug Makers to Promote Drug Discovery Research
May 25, 2017
- Price Band Rule Raising Prices of Rock-Bottom Generics: Sawai President
May 24, 2017
- Japan Biosimilar Association Says “Authorized Biosimilars” Could Mar Industry Development
May 17, 2017
- Market Price Survey for Off-Year Revision Should “Cover All Products”: JPWA
May 15, 2017
- JGA’s 1st Industry Vision Envisages Consolidation into 4 Biz Models
May 8, 2017
- JPMA to Draw Up Proposals on Continuous Manufacturing: Quality & Technology Committee
April 27, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…